This announcement is a separate document:
Eli Lilly and Co | 8-K: Estimated Third Quarter Acquired In-Process Research and Development and Development Milestone Charges
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.